National Medical Products Administration

The National Medical Products Administration (NMPA) is China's regulatory body for medical products. Per a 2025 Gaorong Capital piece, it approves medical devices for market entry in China — such as Pulnovo Medical's PADN device, which became the country's first First-in-Class original pulmonary hypertension medical device to receive NMPA approval . The agency also oversees drug clinical trials, as noted in 2022 Datong Investment coverage of Triastek's T19, the first 3D-printed drug product in China to secure NMPA IND approval . Elsewhere's corpus does not contain a detailed institutional profile of the NMPA itself.